The recent endorsement of Neuraxpharm's ublituximab (BRIUMVI®) by the National Institute for Health and Care Excellence (NICE) marks a significant step forward in the treatment of relapsing-remitting multiple sclerosis (RRMS). This approval is a notable accomplishment for the European specialty
AbbVie's recent acquisition of Nimble Therapeutics, a Roche spinout specializing in peptide-based oral drugs for immune diseases, represents a strategic move to enhance its already robust immunology pipeline. The $200 million deal is aimed at bolstering AbbVie's portfolio, particularly targeting
The recent endorsement by the National Institute for Health and Care Excellence (NICE) to utilize AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy as a treatment for adults with resectable non-small cell lung cancer (NSCLC) marks a significant milestone in cancer care. This
A recent study spearheaded by University of South Florida (USF) Health researchers, in collaboration with TGH Cancer Institute, has unveiled a potential link between ultra-processed foods and an increased risk of colorectal cancer. Researchers highlighted how these foods may contribute to chronic
In early 2023, the FDA's announcement of a shortage of two critical generic platinum chemotherapy drugs, cisplatin and carboplatin, alarmed the medical community. These drugs have been essential in the treatment of various advanced cancers for over 30 years, particularly lung, head and neck,
Advancements in cancer therapy have brought significant hope, especially with immune checkpoint blockades (ICBs), providing a groundbreaking treatment strategy for advanced cancers. Despite this, the effectiveness of ICBs has often been thwarted by therapeutic resistance, which renders
